Stockscreener 앱 받기
65.39
3.76%
2.37
시간 외 거래:
65.32
-0.07
-0.11%
전일 마감가:
$63.02
열려 있는:
$64.06
하루 거래량:
284.02K
Relative Volume:
0.56
시가총액:
$1.88B
수익:
$234.60M
순이익/손실:
$-13.23M
주가수익비율:
-125.61
EPS:
-0.5206
순현금흐름:
$19.61M
1주 성능:
+1.04%
1개월 성능:
+18.65%
6개월 성능:
+196.69%
1년 성능:
+254.61%
1일 변동 폭
$64.00
$66.01
1주일 범위
$60.92
$66.01
52주 변동 폭
$15.40
$68.39
Anaptysbio Inc Stock (ANAB) Company Profile
명칭
Anaptysbio Inc
전화
858-362-6295
주소
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
65.39 | 1.81B | 234.60M | -13.23M | 19.61M | -0.5206 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-06-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-19 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Wells Fargo | Overweight |
| 2024-03-12 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-02-26 | 개시 | BTIG Research | Buy |
| 2024-02-21 | 개시 | Stifel | Buy |
| 2024-02-16 | 개시 | Piper Sandler | Overweight |
| 2023-05-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 개시 | TD Cowen | Outperform |
| 2023-01-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-09-13 | 다운그레이드 | Truist | Buy → Hold |
| 2022-09-01 | 개시 | Raymond James | Outperform |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-22 | 개시 | H.C. Wainwright | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-03-16 | 업그레이드 | Truist | Hold → Buy |
| 2021-03-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-02-11 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2020-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-10-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-11-08 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-11-21 | 개시 | JP Morgan | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-04-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 재확인 | Stifel | Buy |
| 2018-03-06 | 재확인 | Stifel | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2018-01-23 | 재확인 | Credit Suisse | Outperform |
| 2017-11-15 | 개시 | SunTrust | Buy |
| 2017-11-09 | 개시 | Jefferies | Buy |
| 2017-10-11 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
Analysis Recap: Can AnaptysBio Inc grow without external fundingRecession Risk & Weekly High Return Stock Forecasts - baoquankhu1.vn
Investment Report: Can AnaptysBio Inc reach all time highs this yearLong Setup & Daily Price Action Insights - baoquankhu1.vn
RSI Check: Will AnaptysBio Inc benefit from geopolitical trends2026 Year in Review & Capital Efficient Trade Techniques - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Sees Unusually-High Trading Volume – Should You Buy? - Defense World
ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal - MSN
Tranche Update on AnaptysBio, Inc.'s Equity Buyback Plan announced on March 24, 2025. - marketscreener.com
AnaptysBio (NASDAQ:ANAB) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Aug Levels: Does AnaptysBio Inc stock have upside surprise potential2026 Recap & Low Drawdown Investment Strategies - baoquankhu1.vn
ANAB Rating Boost: UBS Raises Price Target to $90 | ANAB Stock N - GuruFocus
UBS Group Issues Positive Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
UBS raises AnaptysBio stock price target to $90 on pipeline upside - Investing.com Australia
UBS raises AnaptysBio stock price target to $90 on pipeline upside By Investing.com - Investing.com South Africa
AnaptysBio, Inc. $ANAB Shares Purchased by Granahan Investment Management LLC - MarketBeat
AnaptysBio Hits New 12-Month High - National Today
How (ANAB) Movements Inform Risk Allocation Models - Stock Traders Daily
AnaptysBio (NASDAQ:ANAB) Hits New 12-Month HighShould You Buy? - MarketBeat
AnaptysBio stock hits 52-week high at 66.73 USD By Investing.com - Investing.com Australia
Psoriasis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | AnaptysBio, Nimbus Lakshmi, Takeda, MoonLake Immunotherapeutics, Can-Fite Biopha - Barchart
AnaptysBio stock hits 52-week high at 66.73 USD - Investing.com
Adaptive Biotechnologies (ADPT) Rises 5.8%: Can This Momentum Continue? - Bitget
First Light Asset Management Reduces Stake in AnaptysBio - National Today
First Light Asset Management LLC Sells 2,549,432 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
HC Wainwright & Co. Maintains AnaptysBio (ANAB) Buy Recommendation - MSN
Aug Fed Impact: Can AnaptysBio Inc grow without external funding2026 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn
AnaptysBio (ANAB): Wedbush Raises Price Target to $75 with Outpe - GuruFocus
Wedbush Forecasts Strong Price Appreciation for AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
Wedbush Raises Price Target on AnaptysBio to $75 From $60, Keeps Outperform Rating - marketscreener.com
AnaptysBio Details First Tracks Bio Spin-Off, Jemperli Royalty Surge and GSK Litigation Timeline - MarketBeat
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighWhat's Next? - MarketBeat
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible - MarketBeat
Barclays Initiates Coverage of AnaptysBio (ANAB) with Overweight Recommendation - MSN
ANAB: Biopharma spin-off advances antibody pipeline as royalty business leverages Jemperli growth - TradingView
ANAB: Truist Securities Maintains Hold Rating, Raises Price Targ - GuruFocus
AnaptysBio, Inc. $ANAB Shares Sold by Citigroup Inc. - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio, Inc. Experiences Revision in Its Stock Evaluation Amid Market Trends - Markets Mojo
Truist raises AnaptysBio stock price target to $50 on Jemperli outlook - Investing.com Canada
Truist Adjusts Price Target on AnaptysBio to $50 From $36, Maintains Hold Rating - marketscreener.com
What is HC Wainwright's Estimate for AnaptysBio Q1 Earnings? - MarketBeat
Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress - Yahoo Finance
AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative - Sahm
Trading Systems Reacting to (ANAB) Volatility - Stock Traders Daily
AnaptysBio stock hits 52-week high at 57.86 USD By Investing.com - Investing.com Nigeria
HC Wainwright Weighs in on AnaptysBio FY2030 Earnings - MarketBeat
AnaptysBio, Inc. Hits New 52-Week High of $62.69, Up 156% - Markets Mojo
AnaptysBio Stock Soars 14.61%, Hits Intraday High of $62.69 - Markets Mojo
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $85.00 at Stifel Nicolaus - MarketBeat
Stifel Raises Price Target for AnaptysBio (ANAB) to $85, Reaffir - GuruFocus
AnaptysBio stock hits 52-week high at 57.86 USD - Investing.com South Africa
AnaptysBio Says R&D Spinout May Launch By April - Citeline News & Insights
Anaptysbio Inc (ANAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):